Equities research analysts at StockNews.com began coverage on shares of OpGen (NASDAQ:OPGN – Get Free Report) in a research note issued to investors on Saturday. The brokerage set a “sell” rating on the medical research company’s stock.
OpGen Stock Performance
OPGN opened at $1.70 on Friday. OpGen has a 1 year low of $1.46 and a 1 year high of $9.90. The stock’s 50 day simple moving average is $1.87 and its 200 day simple moving average is $2.68.
OpGen (NASDAQ:OPGN – Get Free Report) last issued its earnings results on Monday, August 19th. The medical research company reported ($1.18) earnings per share (EPS) for the quarter. The firm had revenue of $0.03 million for the quarter.
About OpGen
OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.
Read More
- Five stocks we like better than OpGen
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Dot Ai IPO: CEO Ed Nabrotzky Shares Vision for Logistics Future
- Trading Halts Explained
- The Hottest Markets to Watch After the Fed’s 25 Bps Rate Cut
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- The Top 5 Performing S&P 500 Stocks YTD in 2024
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.
